These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 1911618)

  • 21. Kell hemolytic disease of the newborn: A case for expanded prenatal antibody screening.
    Spivey MA; Wilson JT; Taylor HL
    J Ark Med Soc; 1978 Jul; 75(2):73-5. PubMed ID: 149785
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of hemolytic disease of the newborn caused by anti-Kell antibody with recombinant erythropoietin.
    Dhodapkar KM; Blei F
    J Pediatr Hematol Oncol; 2001 Jan; 23(1):69-70. PubMed ID: 11196277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The significance of anti-Kell sensitization in pregnancy.
    Mayne KM; Bowell PJ; Pratt GA
    Clin Lab Haematol; 1990; 12(4):379-85. PubMed ID: 2081378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Haemolytic disease of the newborn--from a mother with anti-Kell, anti-E and anti-Vel anti-erythrocyte alloantibodies].
    Vućinović M; Jadrić H; Karelović D; Roje D; Haspl-Hundrić Z; Hrgović Z; Vućinović Z
    Z Geburtshilfe Neonatol; 2004 Oct; 208(5):197-202. PubMed ID: 15508054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pancytopenia due to suppressed hematopoiesis in a case of fatal hemolytic disease of the newborn associated with anti-K supported by molecular K1 typing.
    Wagner T; Resch B; Reiterer F; Gassner C; Lanzer G
    J Pediatr Hematol Oncol; 2004 Jan; 26(1):13-5. PubMed ID: 14707704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Death in utero due to Kell sensitization without excessive elevation of the delta OD450 value in amniotic fluid.
    Berkowitz RL; Beyth Y; Sadovsky E
    Obstet Gynecol; 1982 Dec; 60(6):746-9. PubMed ID: 7145281
    [No Abstract]   [Full Text] [Related]  

  • 27. Anti-Kell in pregnancy.
    Leggat HM; Gibson JM; Barron SL; Reid MM
    Br J Obstet Gynaecol; 1991 Feb; 98(2):162-5. PubMed ID: 2004052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Irregular blood group antibodies during pregnancy: screening is mandatory].
    Semmekrot BA; de Man AJ; Boekkooi PF; van Dijk BA
    Ned Tijdschr Geneeskd; 1999 Jul; 143(28):1449-52. PubMed ID: 10443258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Rapid and severe development of fetal hemolytic disease due to anti-Kell antibodies].
    Frère MC; Schaaps JP; Thoumsin H; Retz MC; Rif J; Rigo J; De Cortis T; Lambotte R; Senterre J; Sondag-Thull D
    Rev Med Liege; 1995 Feb; 50(2):63-6. PubMed ID: 7899747
    [No Abstract]   [Full Text] [Related]  

  • 30. Causes of fetal anemia in hemolytic disease due to anti-K.
    Daniels G; Hadley A; Green CA
    Transfusion; 2003 Jan; 43(1):115-6. PubMed ID: 12519439
    [No Abstract]   [Full Text] [Related]  

  • 31. Hemolytic disease of the newborn: progenitor cells and late effects.
    Luban NL
    N Engl J Med; 1998 Mar; 338(12):830-1. PubMed ID: 9504946
    [No Abstract]   [Full Text] [Related]  

  • 32. Obstetric outcome after RhD and Kell testing.
    Lipitz S; Many A; Mitrani-Rosenbaum S; Carp H; Frenkel Y; Achiron R
    Hum Reprod; 1998 Jun; 13(6):1472-5. PubMed ID: 9688374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Three non-classical mechanisms for anemic disease of the fetus and newborn, based on maternal anti-Kell, anti-Ge3, anti-M, and anti-Jr
    Ohto H; Denomme GA; Ito S; Ishida A; Nollet KE; Yasuda H
    Transfus Apher Sci; 2020 Oct; 59(5):102949. PubMed ID: 32994126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Possible suppression of fetal erythropoiesis by the Kell blood group antibody anti-Kp(a).
    Tuson M; Hue-Roye K; Koval K; Imlay S; Desai R; Garg G; Kazem E; Stockman D; Hamilton J; Reid ME
    Immunohematology; 2011; 27(2):58-60. PubMed ID: 22356520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Serologic incompatibility and family planning].
    Matýsek P; Ungerová A; Cuprová M; Muchová M
    Cesk Gynekol; 1988 Aug; 53(7):497-9. PubMed ID: 3168017
    [No Abstract]   [Full Text] [Related]  

  • 36. [Hemolytic disease of the newborn and irregular blood group antibodies in the Netherlands: prevalence and morbidity].
    van Dijk BA; Hirasing RA; Overbeeke MA
    Ned Tijdschr Geneeskd; 1999 Jul; 143(28):1465-9. PubMed ID: 10443262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Perinatal research on feto-maternal anti-Kell immunization].
    Gavriil P; Jauniaux E; Lambermont M; Donner C; Avni FE; Rodesch F
    J Gynecol Obstet Biol Reprod (Paris); 1989; 18(6):761-4. PubMed ID: 2689503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An innovative test for non-invasive Kell genotyping on circulating fetal DNA by means of the allelic discrimination of K1 and K2 antigens.
    Cro' F; Lapucci C; Vicari E; Salsi G; Rizzo N; Farina A
    Am J Reprod Immunol; 2016 Dec; 76(6):499-503. PubMed ID: 27730708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [SENSITIZATION IN PREGNANCY WITH THE KELL GROUP FACTOR AND THE DISTRIBUTION OF THIS FACTOR].
    UMNOVA MA; PISKUNOVA TM; ICHALOVSKAIA TA
    Akush Ginekol (Mosk); 1963; 39():79-82. PubMed ID: 14085746
    [No Abstract]   [Full Text] [Related]  

  • 40. Chorionic biopsy in management of severe Kell alloimmunization.
    Rodesch F; Lambermont M; Donner C; Simon P; Romasco F; Schwers J; Wybran J
    Am J Obstet Gynecol; 1987 Jan; 156(1):124-5. PubMed ID: 3799745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.